IL22 and psoriasis: Epidermis models based on Ker-CT_STAT3 responded to IL-22 with stronger expression of the psoriasis marker S100A7, with more pronounced acanthosis and with an increased metabolic activity compared to the wild-type cell line Ker-CT (Figure 3).